Pmgc Holdings Inc. · NASDAQ:ELAB
Pmgc — Investor Presentation (February 2025)
16 slides from Pmgc's investor presentation, Feb 7, 2025
Slide 1: A PMGC Holdings Company (NASDAQ: ELAB)
A PMGC HOLDINGS C OMPANY (NA SDAQ: ELAB)
Slide 2: Disclaimer and Forward-Looking Statements
The information in this presentation is being provided so you can familiarize yourself with PMGC Holdings, Inc . ("PMGC", or the "Company," "we," "us," or "our") . We request that you keep the information herein provided confidential and that you do not disclose any of the information to any other p
Slide 3: NorthStrive Biosciences Summary
NorthStrive Biosciences, a newly formed division of PMGC Holdings, focuses on the advancement of therapeutics for obesity and aesthetics. Recently licensed lead asset, EL - 22, a first - in - class approach to address obesity's pressing issue of preserving muscle while on GLP - 1 treatments. Activel
Slide 4: The Unmet Need in Obesity
The Unmet Need in Obesity Past GLP - 1 studies show that ~40% of the weight loss is due to loss of lean muscle1 Physicians have expressed concern that patients may lose muscle on the way down and then replace it with fat on the way up, once off GLP - 1 therapies. LIRAGLUTIDE PORCENTAGE (%) 25 0 - 20
Slide 5: The Opportunity: Myostatin and Activin A
THE OPPORTUNITY: MYOSTATIN ACTVIN A Activin receptor (IIB) Nucleus Satellite Cell Quiescence Why Myostatin? Combination approaches : using GLP - 1 to selectively eliminate fat mass and targeting the Myostatin & Activin signaling pathway to preserve muscle . Myostatin and Activin A bind to the Activi
Slide 6: Product Development Pipeline
Product Development Pipeline Pre - Clinical EL - 22 Myostatin Engineered Probiotic EL - 32 Dual Myostatin/Activin - A Engineered Probiotic Phase I Phase II
Slide 7: EL-22 Mechanism of Action
EL - 22 Mechanism of Action Oral administration 1 Engineered lactobacillus casei expresses modified human myostatin antigen on surface. 2 Administered as oral therapeutic vaccine that dissolves in the small intestine tract . 3 Drug is distributed to the Peyer's patches through M - cells present in t
Slide 8: EL-22 Preclinical Data in DMD Mice
WT= wild - type group TG= transgenic mdx group Treatment= EL - 22 group. All data are represented as mean ц SEM. * p < 0.05 and *** p < 0.001 vs. WT; ## p < 0.01, and ### p < 0.001 vs. TG. International Journal of Molecular Sciences Publication: A New Method of Myostatin Inhibition in Mice via Oral
Slide 9: EL-22 Increased Antibodies and Lowered Muscle Destruction
Anti - myostatin IgG antibody concentration in the serum of the EL - 22 administration group was 0.51 + - 0.02IU/L compared to the control group (p<0.001). Serum Creatine Kinase, which reflects muscle destruction, was significantly decreased in the EL - 22 administration group with average of 1/3 of
Slide 10: Lead Asset Historical Phase I Data
Lead Asset Historical Phase 1 Data Randomized, Double - blind, Placebo - controlled and Dose - escalation Phase I Clinical Trial to Evaluate Safety of BLS - M 22 , Following Single/Multiple Oral Administration in Healthy Adult Volunteers . ClinicalTrials.gov ID: NCT03789734 Enrolment: 37 subjects St
Slide 11: EL-32 Engineered Probiotic with Dual Antigens
EL - 32 is an engineered probiotic with dual Myostatin & Activin - A antigens expressed on the surface to elicit an immune response Induce anti - Myostatin & Activin - A antibodies by active immunization Planning oral administration Preclinical mouse data Target indication: obesity & sarcopenia EL -
Slide 12: EL-32: Preclinical Data in Healthy Mouse Model
Statistically significant Activin A antibodies (p= 0 . 0034 ) and myostatin antibodies (p= 0 . 0047 ) were produced simultaneously, confirming the efficacy using the ELISA test . EL - 32: Preclinical Data in Healthy Mouse Model 5 4 3 2 1 0 0.D 450nm P=0.0034 NT MCS pAld - Myo - Act Anti Activin IgG
Slide 13: Competitive Advantages
NorthStrive Biosciences believes its assets would be the only oral Myostatin formulations to date and be early movers in the emerging GLP - 1 combination space. Myostatin blocker with clinical data and preclinical dual Myostatin/Activin - A blocker. Two Asset with pipeline potential A combination th
Slide 14: NorthStrive Biosciences Team and Scientific Advisory Board
NorthStrive Biosciences Team Scientific Advisory Board Orian Shirihai, MD, PhD Roger A. Fielding, PhD Eduardo Grunvald, MD
Slide 15: Expected Milestones
Expected Milestones 2025 - Pre - IND meeting - Announce cGMP partner - Recruit team members 2026 - EL - 32 IND - Announce strategic collab. PoC Data Readout - Run Preclinical GPL - 1 Combination Studies for EL - 22 and EL - 32 - EL - 22 IND filing - Expand Northstrive Pipeline - Initiate EL - 22 + G
Slide 16: www.northstrivebio.com | IR@pmgcholdings.com
WW W. NORTHS TRIVEBIO. C OM IR@PMGCHOLDINGS .C O M
PMGC Holdings — Investor Presentation (February 2025) on 6ix